Cellebrite (CLBT) Q4 2025 earnings review
Record Profits, M&A Boosts Top Line, but Retention Bleeds
Cellebrite delivered a strong bottom-line quarter, with Adjusted EBITDA margins hitting nearly 30% and free cash flow generation surging. Top-line growth of 21% in ARR looks robust on the surface, but the quality of that growth is mixed: organic ARR growth decelerated to 17%, with the Corellium acquisition bridging the gap. While management touts 'record results,' the steady erosion of Net Retention Rate (NRR) from 124% a year ago to 116% today indicates that despite the 'Inseyets' upgrade cycle, existing customer wallet share expansion is slowing significantly.
🐂 Bull Case
Execution on margins is flawless. Adjusted EBITDA margin expanded to 29.8% (up from 26.4% YoY), and the company converted a massive 64% of Q4 revenue into Free Cash Flow. FY25 FCF margin finished at 33.7%, proving the business model is highly cash-generative.
Management is effectively using its cash pile to buy growth and TAM. The Corellium acquisition (closed Dec 1) contributed ~$16M ARR immediately, and the newly announced SCG Canada acquisition opens the fast-growing Drone Forensics market ($53B projected market by 2026).
🐻 Bear Case
Dollar-based Net Retention Rate (NRR) has declined for five consecutive quarters, falling from 124% in 24Q4 to 116% in 25Q4. This suggests the 'upsell' engine is sputtering despite the ongoing migration to the premium Inseyets platform.
Management explicitly cited a 'challenging U.S. Federal spending environment' as a headwind throughout 2025. While they anticipate a rebound in 2026, the lack of immediate visibility makes this a risk factor.
⚖️ Verdict: ⚪
Neutral. The financial discipline is elite, and M&A is smartly plugging growth gaps. However, the consistent deceleration in organic growth (17%) and NRR (116%) prevents a higher score until the US Federal sector re-accelerates.
Key Themes
Net Retention Rate (NRR) Deterioration
Decelerating. A SaaS company's health is often measured by its ability to upsell existing customers. Cellebrite's NRR has dropped consistently: 124% (24Q4) -> 121% -> 120% -> 117% -> 116% (25Q4). This 800bps compression over 12 months contradicts the narrative that the Inseyets upgrade cycle is a massive revenue multiplier.
Aggressive TAM Expansion (Drones & Crypto)
Management is moving beyond mobile phones. The acquisition of Corellium (virtualization) and the new agreement to buy SCG Canada (Drone Forensics) shows a clear strategy to dominate the entire digital evidence chain. Drone spending is expected to grow 20% to $53.5B in 2026, giving Cellebrite a new secular tailwind.
Inseyets Migration Ahead of Schedule
Accelerating. The company converted 55% of its installed base to the new Inseyets platform by year-end, beating the internal target of 50%. This verifies product-market fit for the new flagship offering, even if it hasn't fully arrested the NRR decline yet.
Organic Growth Slowdown
While headline ARR growth is 21%, the organic figure is 17%. This marks a deceleration from the ~26% organic growth rates seen in late FY24. The reliance on acquired ARR (Corellium contributed $16.1M) to maintain 20%+ growth optics is a yellow flag.
Federal Government Reliance
Stable/Negative. The 'challenging U.S. Federal spending environment' mentioned in the press release continues to weigh on results. The bull case for 2026 relies heavily on an 'anticipated rebound' in this sector, which is not guaranteed given current fiscal tightening.
Other KPIs
Accelerating. Up from 26.4% a year ago and 24.6% in Q2. Management is demonstrating significant operating leverage, allowing profit growth to outpace revenue growth.
Accelerating. FY25 FCF margin reached 33.7%, up from 30.8% in FY24. The Q4 standalone cash generation was exceptional at $82.8M (64% margin), driven by strong collections and seasonality.
Stable. Grew 21% YoY, outpacing total revenue growth of 18%. Subscription now accounts for ~90% of total revenue, improving visibility.
Guidance
Accelerating. Implied growth of 19-20% YoY, which is an acceleration compared to the 17% organic growth seen in Q4. This guidance assumes the US Federal rebound materializes and integrates Corellium/SCG revenue.
Stable. Implies a margin of 26-27%. This is effectively flat to slightly down compared to the Q3 (29.9%) and Q4 (29.8%) FY25 actuals, likely due to integration costs of recent acquisitions and conservative planning.
Decelerating. Implies 18-19% YoY growth. This is lower than the 21% reported in FY25, confirming that the high-growth phase of >25% is likely over without further significant M&A.
Key Questions
NRR Stabilization
Net Retention has dropped for five straight quarters to 116%. At what level do you expect this to trough, and is the weakness driven by the Federal slowdown or a lack of upsell traction in the broader base?
Organic vs. Inorganic Growth
With organic ARR growth slowing to 17%, how much of the FY26 guidance (19-20% growth) is reliant on the Corellium and SCG acquisitions versus a re-acceleration of the core business?
Federal Visibility
You referenced an 'anticipated rebound' in US Federal spending. What specific signals or budget allocations have you seen to give you confidence this will occur in early 2026 rather than later?